What Happened to Silicon Valley Bank?

 

By now, everyone’s heard the Silicon Valley Bank collapse story. Its repercussions are, at present, still sending shockwaves across the banking system, leaving the experts, pundits, the Fed, and everyone wondering if another pillar will drop or can the system hold together.

While the collapse of Silicon Valley Bank (SVB) seemingly happened overnight, were there warnings and red flags indicating they were in trouble? In 2022, SVB began borrowing from the Federal Home Loan Banks system to the tune of $15 billion. Many consider the FHLB loan program a lastditch effort for a bank in trouble, raising more questions about the lack of monitoring and oversight.

Tim Snyder, Economist at Matador Economics and host of Gasonomics, said rising interest rates and inflation negatively impacted SVB’s liquidity.

“The economic impact from rising prices is one issue for the bank, but how inflation has affected its borrowers, especially its startups, are of specific concern,” Snyder said.

The primary business model for SVB is investment in startups. The very nature of startups poses a risk, which raises another critical question, did SVB do enough to hedge their assets, and if not, why weren’t safeguards put into place?

“SVB has a portfolio full of techsector operations and startups. Startups in this sector are notoriously laden with debt, especially early on in their development, so we consider them interestrate sensitive,” Snyder said. “It has been reported that Silicon Valley Bank is the sixteenth largest bank in this country. It did not have a liability management program or hedging program to manage risk. These types of programs are considered the industry standard. It is concerning, and bears some investigation, to determine why they were not in place, and in effect, especially in a time of rising interest rates.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More